about
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphomaComplete remission of gastric Burkitt's lymphoma after eradication of Helicobacter pyloriGenome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphomaPrognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapyYoung patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELAAn international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL studyPralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study.Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial.EZH2 alterations in follicular lymphoma: biological and clinical correlations.Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.[18F]-FDG positron imaging in clinical management of lymphoma patients.Sarcoidosis occurring after lymphoma: report of 14 patients and review of the literature.Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis.The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice.Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma.Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA.Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA StudiesMinimal change nephrotic syndrome associated with non-Hodgkin lymphoid disorders: a retrospective study of 18 cases.Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELAValue of [18F]fluorodeoxyglucose-positron emission tomography in managing patients with aggressive non-Hodgkin's lymphoma.Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.Whole body MRI and PET/CT in haematological malignancies.The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab.Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trialPatients with plasma cell disorders examined at whole-body dynamic contrast-enhanced MR imaging: initial experience.The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid developmentEvent-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.Whole-body diffusion-weighted imaging in lymphoma.Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials.Follicular peripheral T-cell lymphoma expands the spectrum of classical Hodgkin lymphoma mimics.Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GFolliculotropic T-cell infiltrates associated with B-cell chronic lymphocytic leukaemia or MALT lymphoma may reveal either true mycosis fungoides or pseudolymphomatous reaction: seven cases and review of the literature.[Clinical research activity of the French cancer cooperative network: Overview and perspectives].
P50
Q24672476-AB535C70-3DED-4C4F-8E9C-E6728C935860Q27490494-563FE36C-5A11-4E6C-9E36-5AF8F3038EEFQ28248768-5FEF2DA6-232C-413C-9C4E-875A12AFAC42Q28264286-4E957235-03AE-4CB4-B706-01F0C2A38BBEQ30868666-81D34A2E-5105-47EF-BE51-559D4CB9C864Q31364111-F8270C20-7F98-4E79-95E4-041FF2764F04Q33385353-527FAF9D-0EAC-4407-B3B8-18F51FB89324Q33393623-20FC7C28-869E-4E51-B8E4-2CC6E8AD20CBQ33393701-7D79D515-7639-4E7D-A5ED-E2B6B49FF747Q33400977-F58817FB-4170-4F9C-9C97-F2BDA178EE36Q33408175-47C21AA2-42B4-4904-960F-570FB747E508Q33410282-87A27AFA-7B23-475D-9ADB-12F4FEF8F38AQ33438039-65AF594A-1EE6-4980-8502-279940A10237Q33503045-74DBEC99-6DFE-49E5-807B-37915C74E08BQ33701840-7B07DC8D-6ADA-4EF4-8BBF-7C0637FD96ADQ34156097-EACD26B5-8CDE-43AB-B6E6-6F668B117344Q34258569-03B57D92-62BE-405A-A340-87C923E9BFD8Q34446894-3DFD2B3B-BB5E-4234-B5E1-A6326DADC4A7Q34543376-4A407FB0-315B-4886-8831-CA335343D400Q34636362-3AE2AEB5-7E9F-4686-A889-85B7106CE03BQ35095028-F4CD5F10-8FC5-4EB5-81C5-2F2ED089744EQ35143471-FD9BA7BE-B853-469A-8687-04D42049C225Q35501693-676A8E59-0424-45A9-9F5B-331BFD7955ADQ36150869-D131EB40-3280-416D-BDF2-3760BD4D8D83Q36366982-FDE90D80-ACB2-466B-9E11-C9CD7847187BQ36409184-93279B16-55F3-4BC9-AF29-9F8C781AF567Q36591293-487C5B0A-F45C-4CC9-85EE-BCC64A089B1AQ36941044-01B04138-2D4F-453C-8E9D-9A188CCD5C3DQ36963742-487791D7-82DC-4278-9EFA-D8153906253FQ37174123-773D133D-46A7-4771-9586-1DA254F1E2B1Q37273186-40FFF4DE-0B82-4089-BB85-10F76009BF29Q37401565-C1B8F073-0360-474C-A8F1-F956EB3B0DD6Q37549960-DA3EF869-0F3F-4893-A7D3-C6E8FB1226F4Q37662238-EBE3C6B5-1029-44C1-87EE-65DB1004C9AEQ37794481-8F186BA4-8FB4-4253-B8D9-4B7F562672A5Q38050433-C7808EDE-BA56-41F2-A702-EA6171273FBEQ38052774-8B51EBDB-3005-40F7-91BE-12855B0AF531Q38056487-136EC860-E32C-485A-99F9-40BF43A25910Q38197266-F4646ADF-14A9-4D96-A14D-592A59184BE6Q38369864-9E9F947F-B9C1-4F85-9EAE-A4E57AB3CD5E
P50
description
researcher ORCID ID = 0000-0003-0095-5379
@en
wetenschapper
@nl
name
Corinne Haioun
@ast
Corinne Haioun
@en
Corinne Haioun
@es
Corinne Haioun
@nl
type
label
Corinne Haioun
@ast
Corinne Haioun
@en
Corinne Haioun
@es
Corinne Haioun
@nl
prefLabel
Corinne Haioun
@ast
Corinne Haioun
@en
Corinne Haioun
@es
Corinne Haioun
@nl
P31
P496
0000-0003-0095-5379